Hanall Biopharma Co (XKRX:009420) Total Liabilities : ₩53,529 Mil (As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Total Liabilities?

Hanall Biopharma Co's Total Liabilities for the quarter that ended in Dec. 2023 was ₩53,529 Mil.

Hanall Biopharma Co's quarterly Total Liabilities declined from Jun. 2023 (₩49,927.70 Mil) to Sep. 2023 (₩43,630.32 Mil) but then increased from Sep. 2023 (₩43,630.32 Mil) to Dec. 2023 (₩53,528.62 Mil).

Hanall Biopharma Co's annual Total Liabilities increased from Dec. 2021 (₩34,985.66 Mil) to Dec. 2022 (₩45,194.77 Mil) and increased from Dec. 2022 (₩45,194.77 Mil) to Dec. 2023 (₩53,528.62 Mil).

Hanall Biopharma Co Total Liabilities Historical Data

The historical data trend for Hanall Biopharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Total Liabilities Chart

Hanall Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

50,965.91

38,858.95

34,985.66

45,194.77

53,528.62

Hanall Biopharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															45,194.77	43,323.11	49,927.70	43,630.32	53,528.62

Hanall Biopharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hanall Biopharma Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37651.87	+	(590.309	+	14728.91
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	557.534)
	=	53,529

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	239746.993	-	186218.37
	=	53,529

Hanall Biopharma Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37651.87	+	(590.309	+	14728.91
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	557.534)
	=	53,529

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	239746.993	-	186218.37
	=	53,529

Hanall Biopharma Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co (XKRX:009420) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR

Website

http://www.hanall.co.kr

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines